# FDA 483 - National Cancer Institute Central IRB - August 09, 2022

Source: https://www.keypedia.com/records/483/national-cancer-institute-central-irb/34541808-bed8-418e-862d-d3b4628a3d0b

> FDA 483 for National Cancer Institute Central IRB on August 09, 2022. Product: other. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: National Cancer Institute Central IRB
- Inspection Date: 2022-08-09
- Product Type: other
- Office Name: Office of Regulatory Affairs
- Summary: An FDA inspection of the National Cancer Institute Central IRB in Rockville, MD, revealed a significant procedural lapse. The Institutional Review Board failed to update its registration information regarding changes in chairperson within the required 90-day timeframe. This resulted in delays of 467 and 106 days for two separate IRB committees.

## Related Officers

- [Consumer Safety Officer/BIMO Investigator](https://www.keypedia.com/people/david-l-chon/227b9c21-14c4-442b-bdc3-ad167567fd92)

Company: https://www.keypedia.com/companies/national-cancer-institute-central-irb/e5835564-ef60-4f01-8bc0-6eeb2da0c380

Office: https://www.keypedia.com/offices/office-of-regulatory-affairs/ff91c598-cf72-4dbe-a2c8-7519c64cbc64